Salat Jones
Psychiatric/Mental Health · Saint Louis, MONPI 1396473294
Payments from drug & device makers
Across 122 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$433
- AbbVie$304
- Otsuka America Pharmaceutical, Inc.$273
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$249
- Alpha Cognition USA, Inc.$193
- Alkermes, Inc.$184
- plus $864 from 12 others
What the payments were for
- Food & beverage$2,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 15 | $433 |
| AbbVie | 24 | $304 |
| Otsuka America Pharmaceutical, Inc. | 15 | $273 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $249 |
| Alpha Cognition USA, Inc. | 8 | $193 |
| Alkermes, Inc. | 8 | $184 |
| Johnson & Johnson | 2 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $126 |
| Lundbeck LLC | 4 | $92 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Noven Therapeutics, LLC | 4 | $68 |
| Almatica Pharma LLC | 4 | $65 |
| Tris Pharma Inc | 4 | $64 |
| Neos Therapeutics, LP | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$146
- INGREZZA$121
How this compares
$2,501 in reported general payments places this provider in the 75th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $154,510 |
| Invega SustennaPaliperidone Palmitate | 51 | $146,435 |
| AristadaAripiprazole Lauroxil | 18 | $33,933 |
| TrintellixVortioxetine Hydrobromide | 39 | $20,092 |
| VraylarCariprazine Hcl | 13 | $18,642 |
| RexultiBrexpiprazole | 13 | $18,561 |
| Clozapine | 35 | $3,316 |
| Varenicline Tartrate | 16 | $2,979 |
| Duloxetine Hcl | 74 | $2,246 |
| Paliperidone ErPaliperidone | 21 | $1,844 |
| Lurasidone Hcl | 14 | $1,500 |
| Bupropion XlBupropion Hcl | 117 | $1,278 |
| Haloperidol Decanoate | 23 | $990 |
| Aripiprazole | 61 | $940 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 78 | $912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $433 | $154,51011 claims |
| Johnson & JohnsonInvega Sustenna | $165 | $146,43551 claims |
| Alkermes, Inc.Aristada | $184 | $33,93318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $126 | $20,09239 claims |
| AbbVieVraylar | $304 | $18,64213 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $273 | $18,56113 claims |
| Almatica Pharma LLCSertraline Hcl | $65 | $16689 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Saint Louis
- Aldijana SacicSaint Louis$510K
- Julie WaterburySaint Louis$135K
- Melinda SmithSaint Louis$13K
- Richard YakimoSaint Louis$10K
- Yevgeniya MykhaylevskaSaint Louis$9K
- Anastasia AmiramovaSaint Louis$9K
- Jessica BurichSaint Louis$8K
- Jennifer ArmstrongSaint Louis$8K
- Bonnie HuffSaint Louis$7K
- Jacqueline KirkSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.